Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany"

Eur J Health Econ. 2018 Apr;19(3):473-481. doi: 10.1007/s10198-018-0956-4. Epub 2018 Feb 21.

Authors

Alexander Kuhlmann¹, J-Matthias Graf von der Schulenburg²

Affiliations

¹ Center for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Otto-Brenner-Straße 1, 30159, Hanover, Germany. ak@ivbl.uni-hannover.de.
² Center for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Otto-Brenner-Straße 1, 30159, Hanover, Germany.

PMID: 29468343
DOI: 10.1007/s10198-018-0956-4

No abstract available

Publication types

Letter
Comment

MeSH terms

Cost-Benefit Analysis*
Germany
Humans
Infant
Pneumococcal Infections
Pneumococcal Vaccines
Vaccination
Vaccines, Conjugate*

Substances

Pneumococcal Vaccines
Vaccines, Conjugate